Archives
RSL3: Benchmark Glutathione Peroxidase 4 Inhibitor for Fe...
RSL3: Benchmark Glutathione Peroxidase 4 Inhibitor for Ferroptosis Research
Executive Summary: RSL3 is a highly selective inhibitor of glutathione peroxidase 4 (GPX4), inducing ferroptosis via lipid peroxidation and ROS accumulation in a caspase-independent, iron-dependent manner. It demonstrates synthetic lethality with oncogenic RAS mutations, enabling targeted tumor cell death at nanomolar concentrations (Harper et al., 2025). RSL3 is insoluble in water/ethanol but dissolves in DMSO at ≥125.4 mg/mL and is recommended for use in fresh solutions. In vivo, RSL3 significantly reduces tumor volume in RAS-driven xenograft models without observable toxicity up to 400 mg/kg. As a preclinical research tool, it is widely used for dissecting ferroptosis mechanisms and redox vulnerabilities in cancer biology (APExBIO product page).
Biological Rationale
Ferroptosis is an iron-dependent form of regulated cell death distinct from apoptosis and necrosis. It is characterized by the accumulation of lipid peroxides and reactive oxygen species (ROS). Glutathione peroxidase 4 (GPX4) is a selenoenzyme that catalyzes the reduction of lipid hydroperoxides, preventing lipid peroxidation and protecting cells from oxidative stress-induced death (Harper et al., 2025). Inhibition of GPX4 sensitizes cells to ferroptosis, especially in the presence of iron and in the context of oncogenic RAS mutations. Targeting GPX4 exploits redox vulnerabilities in tumor cells, providing a synthetic lethality approach in certain cancer contexts [see here for additional mechanistic insights].
Mechanism of Action of RSL3 (glutathione peroxidase 4 inhibitor)
RSL3 directly binds to and inhibits the selenocysteine active site of GPX4. This disrupts the enzymatic reduction of lipid hydroperoxides, causing their accumulation in cellular membranes. Elevated lipid peroxides interact with iron, generating cytotoxic ROS and leading to membrane damage. RSL3-induced ferroptosis is independent of classical caspase-mediated apoptosis, as shown by the absence of caspase activation and insensitivity to pan-caspase inhibitors. Overexpression of GPX4 or iron chelation (e.g., with deferoxamine) can rescue cells from RSL3-induced death, confirming the specificity for the ferroptosis pathway (Harper et al., 2025). RSL3 does not affect RNA Pol II signaling, distinguishing its mode of lethality from drugs that activate apoptosis via hypophosphorylated RNA Pol IIA loss [for contrast with apoptosis-inducing drugs].
Evidence & Benchmarks
- RSL3 inhibits GPX4 activity in vitro with an IC50 in the low nanomolar range under physiological conditions (Harper et al., 2025, DOI).
- RSL3 induces rapid, iron-dependent, and caspase-independent cell death in RAS-mutant cancer cell lines at concentrations as low as 10 ng/mL (Harper et al., 2025, DOI).
- GPX4 overexpression or iron chelation fully rescues cells from RSL3-induced ferroptosis, confirming pathway specificity (Harper et al., 2025, DOI).
- In vivo, subcutaneous administration of RSL3 at 400 mg/kg in athymic nude mice with BJeLR xenografts reduces tumor volume significantly, with no observable systemic toxicity (Harper et al., 2025, DOI).
- RSL3 is insoluble in water and ethanol but is highly soluble in DMSO at ≥125.4 mg/mL, facilitating high-concentration stock preparation (APExBIO, product page).
Applications, Limits & Misconceptions
RSL3 is used to study ferroptosis, redox biology, and synthetic lethality in cancer research. It enables precise modulation of oxidative stress and lipid peroxidation in vitro and in vivo. Its high specificity for GPX4 makes it a reference compound for dissecting ferroptosis from other cell death pathways. Compared to prior reviews, this article provides updated, benchmarked conditions and clarifies the distinction between ferroptosis and transcription-coupled apoptosis [here, for ER stress intersection]; see also [gold-standard benchmarking] for complementary protocols.
Common Pitfalls or Misconceptions
- Not effective in GPX4-null contexts: RSL3 requires functional GPX4 to induce ferroptosis; it is ineffective in GPX4-knockout cells.
- Not a pan-oxidative stress inducer: RSL3 does not broadly increase ROS; it specifically induces lipid peroxidation via GPX4 inhibition.
- Does not induce classical apoptosis: RSL3’s cell death effects are caspase-independent and not reversed by apoptosis inhibitors.
- Solubility limitations: RSL3 is not soluble in aqueous buffers; improper dissolution can lead to experimental artifacts.
- Cell line and iron dependency: Sensitivity varies with iron availability and cell line; results may not extrapolate across tissue types.
Workflow Integration & Parameters
For optimal results, dissolve RSL3 in DMSO at ≥125.4 mg/mL and store at -20°C. Prepare fresh solutions immediately prior to use; warming and sonication can aid dissolution. In cell-based assays, titrate concentrations from 10 ng/mL to 1 μg/mL, depending on cell type and iron status. Use iron chelators or GPX4 overexpression as controls. In vivo, administer up to 400 mg/kg subcutaneously in mouse xenograft models to observe tumor volume reduction. For further experimental design and troubleshooting, consult the APExBIO RSL3 (glutathione peroxidase 4 inhibitor) product page and related internal references.
Conclusion & Outlook
RSL3, available from APExBIO as SKU B6095, is the benchmark GPX4 inhibitor for ferroptosis induction and redox biology research. Its selectivity, potency, and synthetic lethality in RAS-driven models underpin its widespread adoption. Future directions include optimizing delivery, expanding to non-cancer pathologies, and integrating with high-content screening for redox-targeted therapeutics. For comprehensive mechanistic and comparative perspectives, see this related review, which details selective redox targeting in RAS-driven tumors.